297 related articles for article (PubMed ID: 27084761)
21. Benefits and risks of adjunctive inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis.
Sobieraj DM; White CM; Coleman CI
Clin Ther; 2008 Aug; 30(8):1416-25. PubMed ID: 18803985
[TBL] [Abstract][Full Text] [Related]
22. Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD).
Ni H; Htet A; Moe S
Cochrane Database Syst Rev; 2017 Jun; 6(6):CD011897. PubMed ID: 28631387
[TBL] [Abstract][Full Text] [Related]
23. Deterioration of quality of life is associated with the exacerbation frequency in individuals with alpha-1-antitrypsin deficiency - analysis from the German Registry.
Bernhard N; Lepper PM; Vogelmeier C; Seibert M; Wagenpfeil S; Bals R; Fähndrich S
Int J Chron Obstruct Pulmon Dis; 2017; 12():1427-1437. PubMed ID: 28553095
[TBL] [Abstract][Full Text] [Related]
24. Impact of frequency of COPD exacerbations on pulmonary function, health status and clinical outcomes.
Anzueto A; Leimer I; Kesten S
Int J Chron Obstruct Pulmon Dis; 2009; 4():245-51. PubMed ID: 19657398
[TBL] [Abstract][Full Text] [Related]
25. Immunostimulants versus placebo for preventing exacerbations in adults with chronic bronchitis or chronic obstructive pulmonary disease.
Fraser A; Poole P
Cochrane Database Syst Rev; 2022 Nov; 11(11):CD013343. PubMed ID: 36373977
[TBL] [Abstract][Full Text] [Related]
26. Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review.
Westwood M; Bourbeau J; Jones PW; Cerulli A; Capkun-Niggli G; Worthy G
Respir Res; 2011 Apr; 12(1):40. PubMed ID: 21477298
[TBL] [Abstract][Full Text] [Related]
27. Exacerbation frequency and course of COPD.
Halpin DM; Decramer M; Celli B; Kesten S; Liu D; Tashkin DP
Int J Chron Obstruct Pulmon Dis; 2012; 7():653-61. PubMed ID: 23055714
[TBL] [Abstract][Full Text] [Related]
28. Phosphodiesterase-4 inhibitors for chronic obstructive pulmonary disease.
Janjua S; Fortescue R; Poole P
Cochrane Database Syst Rev; 2020 May; 5(5):CD002309. PubMed ID: 32356609
[TBL] [Abstract][Full Text] [Related]
29. Long-acting beta2-agonists for chronic obstructive pulmonary disease.
Kew KM; Mavergames C; Walters JA
Cochrane Database Syst Rev; 2013 Oct; (10):CD010177. PubMed ID: 24127118
[TBL] [Abstract][Full Text] [Related]
30. Tiotropium versus placebo for chronic obstructive pulmonary disease.
Karner C; Chong J; Poole P
Cochrane Database Syst Rev; 2014 Jul; 2014(7):CD009285. PubMed ID: 25046211
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β
Ferguson GT; Darken P; Ballal S; Siddiqui MK; Singh B; Attri S; Holmgren U; de Nigris E
Adv Ther; 2020 Jun; 37(6):2956-2975. PubMed ID: 32335859
[TBL] [Abstract][Full Text] [Related]
32. Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD - mixed treatment comparisons of clinical efficacy.
Stynes G; Svedsater H; Wex J; Lettis S; Leather D; Castelnuovo E; Detry M; Berry S
Respir Res; 2015 Feb; 16(1):25. PubMed ID: 25849223
[TBL] [Abstract][Full Text] [Related]
33. Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA.
Singh D; Fabbri LM; Vezzoli S; Petruzzelli S; Papi A
Int J Chron Obstruct Pulmon Dis; 2019; 14():531-546. PubMed ID: 30880943
[TBL] [Abstract][Full Text] [Related]
34. AZD9668, a neutrophil elastase inhibitor, plus ongoing budesonide/formoterol in patients with COPD.
Kuna P; Jenkins M; O'Brien CD; Fahy WA
Respir Med; 2012 Apr; 106(4):531-9. PubMed ID: 22197578
[TBL] [Abstract][Full Text] [Related]
35. Self-management interventions including action plans for exacerbations versus usual care in patients with chronic obstructive pulmonary disease.
Lenferink A; Brusse-Keizer M; van der Valk PD; Frith PA; Zwerink M; Monninkhof EM; van der Palen J; Effing TW
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD011682. PubMed ID: 28777450
[TBL] [Abstract][Full Text] [Related]
36. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.
Chong J; Leung B; Poole P
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD002309. PubMed ID: 28922692
[TBL] [Abstract][Full Text] [Related]
37. Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis.
Ismaila AS; Haeussler K; Czira A; Tongbram V; Malmenäs M; Agarwal J; Nassim M; Živković-Gojović M; Shen Y; Dong X; Duarte M; Compton C; Vogelmeier CF; Halpin DMG
Adv Ther; 2022 Nov; 39(11):4961-5010. PubMed ID: 35857184
[TBL] [Abstract][Full Text] [Related]
38. Unreported and Overlooked: A Post Hoc Analysis of COPD Symptom-Related Attacks from the RISE Study.
Ferguson GT; Skärby T; Nordenmark LH; Lamarca R; Aksomaityte A; Lythgoe D; Gilbert I; Trudo F
Int J Chron Obstruct Pulmon Dis; 2020; 15():3123-3134. PubMed ID: 33273814
[TBL] [Abstract][Full Text] [Related]
39. Biological effects of p38 MAPK inhibitor losmapimod does not translate to clinical benefits in COPD.
Pascoe S; Costa M; Marks-Konczalik J; McKie E; Yang S; Scherbovsky PS
Respir Med; 2017 Sep; 130():20-26. PubMed ID: 29206629
[TBL] [Abstract][Full Text] [Related]
40. Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis.
Kew KM; Dias S; Cates CJ
Cochrane Database Syst Rev; 2014 Mar; 2014(3):CD010844. PubMed ID: 24671923
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
